MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Cancer blog: Phase 3 trial using talabostat in metastatic non-small cell lung cancer

Return to cancer blog Cancer news Cancer terms  

Oct 15, 2005

Phase 3 trial using talabostat in metastatic non-small cell lung cancer

Phase 3 trial using talabostat  in metastatic non-small cell lung cancer Point Therapeutics, Inc. has announced that it initiated its Phase 3 program in metastatic non-small cell lung cancer (NSCLC). This news follows a successful End-of-Phase 2 meeting with the Food and Drug Administration.

"We are pleased with our End-of-Phase 2 meeting discussions with the FDA and the fact that there were no major changes to the Phase 3 study protocols. We look forward to continuing to clinically develop talabostat in this advanced lung cancer population," said Dr. Margaret Uprichard, chief development officer and senior vice president of Point Therapeutics.

Point's Phase 3 program will further evaluate the company's lead compound, talabostat, in patients with Stage IIIB and IV NSCLC after failure of a platinum-based chemotherapy. The program will consist of two randomized, double-blind, placebo-controlled trials in up to 800 patients at approximately 100 sites in North America. The first 400-patient trial has opened to enrollment. This trial will evaluate talabostat in combination with docetaxel versus docetaxel with placebo.

The second 400-patient trial will evaluate talabostat in combination with pemetrexed versus pemetrexed with placebo. Docetaxel and pemetrexed are the current standard of care in this advanced patient population. The primary study endpoint is progression-free survival. Secondary endpoints include overall survival, objective response rate, complete response, duration of response and quality of life.

"I am encouraged by the positive results in Point's Phase 2 trial of talabostat and docetaxel. As reported at this year's ASCO meeting" said Dr. Casey Cunningham, an oncologist at Mary Crowley Medical Research Center in Dallas. "Five patients demonstrated at least a 50 percent reduction in tumor size, of which two had a complete response, defined as a complete disappearance of their tumor. To see complete responders in a second or third line setting in advanced non-small cell lung cancer is rare and merits further study.

Talabostat is taken orally and has the potential to be used in both solid and hematologic malignancies and in combination with a range of chemotherapies, monoclonal antibodies and other forms of cancer treatment, according to the company.

Contact information
Tel: 617-933-2130
mail to: inquiries@pther.com

Phase II trial results using talabostat

Janet      Return to Cancer Blog Main


Do You Read All Of Our Cancer Blogs?

Do You Read All Of Blogs?
Do you read all of the blogs published by medicineworld.org? Many of our bloggers are busy keeping you updated on the various health related topics. We publish the following blogs at this time.

Cancer blog: I manage the cancer blog with lots of help and support form other bloggers. Through this cancer blog my friends and I try to bring stories of hope for patients with cancer. The cancer blog often republishes important blog posts from other cancer related blogs at Medicineworld.org. If you are searching for a blog that covers wide variety of cancer topics, this may be the one for you.

Breast cancer blog: Breast cancer blog is run by Emily and other bloggers and they bring you the latest stories, news and events that are related to breast cancer. Increasing awareness about breast cancer among women and in the general population is the main goal of this breast cancer blog.

Lung cancer blog: Lung cancer blog is managed by Scott with the help of other bloggers. Through this blog Scott and his friends constantly remind the readers about the dangers of smoking. It's a never-ending struggle against this miserable disease with which a social stigma of smoking is associated.

Colon cancer blog: Colon cancer blog is run by Sue and other bloggers. Sue brings a personal touch to the colon cancer blog since her mother died of colon cancer few years ago. She writes about stories, research news and advances in treatment related to colon cancer.

Prostate cancer blog: Prostate cancer is the most common cancer among American men. American Cancer Society estimates that over 230,000 new cases of prostate cancer occur in the United state every year. This important blog about prostate cancer is run by Mark and other bloggers. This blog brings news, stories, and other personal observations related to prostate cancer.

Medicineworld.org publishes a diabetes watch blog and this blog is run by JoAnn other bloggers. This diabetes watch blog brings you the latest in the field of diabetes. This includes personal stories, advances in diagnosis and treatment, and other observations about diabetes. Improving awareness about diabetes is an important mission of this group.

Heart watch blog: About 13 million Americans suffer from coronary artery disease. Coronary artery disease is the leading cause of death in American men and women amounting a staggering 20 percent of all causes of death. The tremendous responsibility of running a heart blog is entrusted to Daniel. He is creating blog posts with the help and support of other bloggers.

Janet      


Cancer
We do not know the exact cause of many cancers. Many cancers like leukemia have no apparent cause. Some other types of cancers like lung cancers have identifiable causes like smoking in most cases. Lung cancer can occur in those who have never smoked in their life. It is hard to know in these cases what is causing that patients lung cancer. Factors that increase the risk of development of cancer is known as risk factors for cancer. These risk factors may be modifiable like smoking where a person can exert control or un-modifiable factors like age and gender. Smoking can cause cancers of the lungs, mouth, throat, bladder, kidneys and several other organs.

Cancer blog: Phase 3 trial using talabostat in metastatic non-small cell lung cancer

Lung cancer blog| Colon cancer blog| Prostate cancer blog| Cancer terms| History of cancer| Imaging techniques| Cancer Main| Bladder cancer news| Cervix cancer news| Colon cancer news| Esophageal cancer news| Gastric cancer news| Health news| Lung cancer news| Breast cancer news| Ovarian cancer news| Cancer news| Pancreatic cancer news| Prostate cancer news| Endometrial cancer news| General info| What is cancer?| Cancer causes| Is cancer hereditary?| Types of cancer| Cancer statistics| Breast cancer main| Breast cancer symptoms| Colon cancer main| Anal cancer| Bladder cancer main| Lung cancer general| Lung cancer main| Non small cell| Small cell| Ovarian cancer main| Treatment of ovarian cancer| Prostate cancer main|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.